StockData
TG Therapeutics, Inc. logo

TG Therapeutics, Inc. (TGTX) stock

TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$62.71−0.05 (-0.08%)

Close on Nov 17, 2026Market cap $9.60BP/E 22.9Yield –

TG Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

TG Therapeutics's total debt was $745.39M at Jun 30, 2026. For fiscal 2025 it was $245.65M, up 0.5% from the year before. The highest annual figure on record is $245.65M in fiscal 2025.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$245.65M+0.5%
FY2024Dec 31, 2024$244.43M+144.1%
FY2023Dec 31, 2023$100.12M+40.7%
FY2022Dec 31, 2022$71.14M+5.0%
FY2021Dec 31, 2021$67.76M+126.7%
FY2020Dec 31, 2020$29.90M+3.2%
FY2019Dec 31, 2019$28.97M–
FY2018Dec 31, 2018$0–
FY2017Dec 31, 2017$0–
FY2016Dec 31, 2016$0–
FY2015Dec 31, 2015$0–
FY2014Dec 31, 2014$0-100.0%
FY2013Dec 31, 2013$64.53K-97.4%
FY2012Dec 31, 2012$2.48M-24.8%
FY2011Dec 31, 2011$3.29M-79.6%
FY2010Dec 31, 2010$16.13M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$745.39M+204.2%
Q1 FY2026Mar 31, 2026$745.14M+204.5%
Q4 FY2025Dec 31, 2025$245.65M+0.5%
Q3 FY2025Sep 30, 2025$245.34M+0.5%
Q2 FY2025Jun 30, 2025$245.04M+139.0%
Q1 FY2025Mar 31, 2025$244.73M+141.5%
Q4 FY2024Dec 31, 2024$244.43M+144.1%
Q3 FY2024Sep 30, 2024$244.16M+146.9%
Q2 FY2024Jun 30, 2024$102.54M+5.0%
Q1 FY2024Mar 31, 2024$101.33M+5.0%
Q4 FY2023Dec 31, 2023$100.12M+40.7%
Q3 FY2023Sep 30, 2023$98.91M+39.0%
Q2 FY2023Jun 30, 2023$97.70M+41.7%
Q1 FY2023Mar 31, 2023$96.50M+43.5%
Q4 FY2022Dec 31, 2022$71.14M+5.0%
Q3 FY2022Sep 30, 2022$71.14M+344.6%
Q2 FY2022Jun 30, 2022$68.95M+197.7%
Q1 FY2022Mar 31, 2022$67.25M+123.2%
Q4 FY2021Dec 31, 2021$67.76M+126.7%
Q3 FY2021Sep 30, 2021$16.00M-46.1%
Q2 FY2021Jun 30, 2021$23.16M-21.3%
Q1 FY2021Mar 31, 2021$30.13M+3.2%
Q4 FY2020Dec 31, 2020$29.90M+3.2%
Q3 FY2020Sep 30, 2020$29.66M+3.2%
Q2 FY2020Jun 30, 2020$29.43M+3.2%
Q1 FY2020Mar 31, 2020$29.20M+3.2%
Q4 FY2019Dec 31, 2019$28.97M–
Q3 FY2019Sep 30, 2019$28.74M–
Q2 FY2019Jun 30, 2019$28.51M–
Q1 FY2019Mar 31, 2019$28.29M–
Q4 FY2018Dec 31, 2018$0–
Q3 FY2018Sep 30, 2018$0–
Q2 FY2018Jun 30, 2018$0–
Q1 FY2018Mar 31, 2018$0–
Q4 FY2017Dec 31, 2017$0–
Q3 FY2017Sep 30, 2017$0–
Q2 FY2017Jun 30, 2017$0–
Q1 FY2017Mar 31, 2017$0–
Q4 FY2016Dec 31, 2016$0–
Q3 FY2016Sep 30, 2016$0–

More TG Therapeutics figures

See a number that looks wrong?